Technology platform 1: Oncolytic Virus Vaccine (OVV)
Construction of oncolytic virus vaccine (OVV) based on tumor antigen expressed by oncolytic virus (OV)

Technology platform 2: OVV-Drive-IO™, “Mark + Kill”

• Mechanism of Action: OVV expresses a TAA target on tumor cells, “MARK” the tumor cells; Paired with immune cells (such as TCR-T, CAR-T etc.), or antibody, to “KILL” the marked tumor cells for a combination therapy.

• The example of OVV-Drive-IO™: VSV expressing NY-ESO-1, paired with TCR-T targeting NY-ESO-1 for combination therapy, increasing ability to kill tumor cells.

  

• 1) The oncolytic virus vaccine OVV-NY-ESO-1 infects tumor cells, replicates, and remodels the tumor microenvironment.

• 2) Exogenous NY-ESO-1 TCR-T cells are intravenously delivered to the tumor core.
  

• 3) The vaccine induces NY-ESO-1 antigen expression on tumor cells, guiding exogenous NY-ESO-1 TCR-T cells to target and attack them.

• 4) Tumor cell lysis releases viral particles and spreads neoantigen epitopes, recruiting endogenous immune cells to the tumor.

• 5) Released viral particles reinfect nearby tumor cells, starting a new infection-lysis cycle and achieving synergistic effects (1+1>2).